f solid fundamentals in HIV, very significant momentum in hep C, and an oncology pipeline coming into focus. We expect a continued robust launch of Solvadi in hep C given meaningful improvements relative to currently available therapies. We expect the fixed dose combination (FDC) of sofosbuvir + ledipa